MEDIA & INVESTOR RELEASE

Novartis Scemblix^® shows superior major molecular response (MMR) rates vs. standard-of-care TKIs in Phase III trial for newly diagnosed patients with chronic myeloid leukemia

Ad hoc announcement pursuant to Art. 53